Global Hemostatic Agents Market Size By Type (Thrombin-based, Gelatin-based, Collagen-based, Oxidized Regenerated Cellulose-based, Combination, Fibrin Sealants), By Product (Active, Passive, Combination), By Application (Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery), By End-User (Hospitals, Surgery Centers, Nursing Homes), By Geographic Scope And Forecast

Hemostatic Agents Market Size And Forecast

Hemostatic Agents Market size was valued at USD 4.3 Billion in 2024 and is projected to reach USD 6.49 Billion by 2031, growing at a CAGR of 5.30% from 2024 to 2031.

• Hemostatic agents are materials used to control bleeding quickly and effectively during surgeries or in emergency situations. They function by concentrating coagulation factors, attaching to tissues where hemorrhage has occurred, or supplying procoagulant factors to the bleeding site. Hemostatic agents are characterized as mechanical, active, or passive.
• They are used to treat uncontrollable large bleeding in the absence of clotting factors, coagulation abnormalities, hemorrhage caused by trauma, cerebral hemorrhage, postpartum hemorrhage, and bleeding during or after major surgeries.

To Get Detailed Analysis: Download Report PDF

Global Hemostatic Agents Market Dynamics

The key market dynamics that are shaping the hemostatic agents market include:

Key Market Drivers

• Increasing number of Surgical Procedures: The growing number of surgical operations worldwide is a major driver of the hemostatic agents market. According to the World Health Organization (WHO), the number of procedures conducted worldwide has constantly increased. According to a study published in The Lancet, 313 million surgical procedures were performed worldwide in 2012, with the figure expected to rise to 458.4 million in 2030. The increase in surgical operations, many of which require good hemostasis, is pushing up demand for hemostatic agents.
• Rising Prevalence of Bleeding Disorders: The growing prevalence of bleeding diseases is driving up the demand for hemostatic agents. According to the World Federation of Hemophilia (WFH), hemophilia affects approximately one out of every 10,000 persons worldwide. In their 2019 Annual Global Survey, the WFH found 324,648 people worldwide living with bleeding disorders, a 6% rise over the previous year. The expanding patient population with bleeding disorders necessitates the use of hemostatic agents in a variety of clinical settings.
• Increasing Traumatic Injuries and Emergency Cases: The increased prevalence of traumatic injuries, notably from automobile accidents, is propelling the hemostatic agents market. According to the World Health Organization’s Global Status Report on Road Safety 2018, roughly 1.35 million people die each year as a result of road traffic accidents, with another 20-50 million suffering non-fatal injuries. Many of these injuries necessitate urgent hemostasis, which increases the need for hemostatic agents in emergency and trauma care settings.

Key Challenges:

• High Cost of Hemostatic Agents: Hemostatic agents are expensive, which is another major barrier, especially in developing nations where funds for healthcare are few. Many modern hemostatic products are expensive, rendering them inaccessible to hospitals and clinics that cannot pay the costs. This financial barrier impedes the adoption of good medicines in critical situations, affecting patient outcomes and overall market growth.
• Risk of Adverse Reactions: The potential for adverse reactions to certain hemostatic medicines also limits market growth. Healthcare experts are hesitant to utilize these products because they are concerned about potential adverse effects such as allergic responses and tissue damage. This concern leads to a preference for existing hemostasis procedures, restricting the market’s acceptance and use of new hemostatic agents.

Key Trends:

• Increasing Adoption of Minimally Invasive Surgeries: The growing popularity of minimally invasive operations is having a significant impact on the hemostatic agents market. As surgical techniques advance, there is an increasing preference for operations that reduce tissue stress and recuperation time. Hemostatic medicines are essential in these situations because they help control bleeding while protecting surrounding tissues. This development is generating demand for novel hemostatic agents designed specifically for minimally invasive treatments.
• Technological Advancements: Technological developments in hemostatic agents are influencing the market landscape. Manufacturers are spending in R&D to develop more effective and safe products, such as enhanced formulations and delivery technologies. Combination hemostats, which have numerous mechanisms of action, are gaining traction. These developments not only improve patient outcomes but also broaden the applications of hemostatic agents across various surgical specialties.
• Growing Prevalence of Chronic Diseases: The increasing frequency of chronic diseases, combined with an aging population, is driving up demand for hemostatic agents. Chronic illnesses necessitate surgical procedures, resulting in a higher incidence of surgeries where bleeding management is essential. As the world’s population ages, the number of surgical procedures is predicted to increase, boosting the market for hemostatic agents. This trend underscores the importance of appropriate bleeding management systems in healthcare settings.

What's inside a VMR
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

>>> Ask For Discount @ – https://www.verifiedmarketresearch.com/ask-for-discount/?rid=40203

Global Hemostatic Agents Market Regional Analysis

Here is a more detailed regional analysis of the hemostatic agents market:

North America:

• According to Verified Market Research, North America is estimated to dominate the hemostatic agents market over the forecast period. North America has a high prevalence of cardiovascular disease, which necessitates a large number of cardiac procedures that require hemostatic agents. According to the American Heart Association’s 2021 Heart Disease and Stroke Statistics update, about half of all American adults suffer from cardiovascular disease. According to the report, heart disease kills over 659,000 people in the United States each year, accounting for one out of every four deaths. Also, the Society of Thoracic Surgeons states that roughly 500,000 coronary artery bypass graft surgeries are conducted each year in the United States. This large volume of cardiac surgeries increases the demand for sophisticated hemostatic agents in the region.
• Furthermore, North America has a high rate of traumatic injuries, mainly from car accidents and violence, necessitating the usage of hemostatic agents in emergency situations. According to the National Center for Health Statistics, unintentional injuries are the third greatest cause of death in the United States, with around 173,040 deaths in 2019. Also, the National Trauma Institute reports that trauma accounts for 41 million emergency department visits and 2.3 million hospital admissions across the country each year. This high volume of trauma patients greatly increases the demand for hemostatic agents in North America.

Asia Pacific:

• The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia-Pacific region has a high rate of traffic accidents, which result in traumatic injuries requiring hemostatic agents. According to the World Health Organization’s Global Status Report on Road Safety 2018, Southeast Asia and the Western Pacific regions account for 62% of all road traffic deaths. In China alone, the Ministry of Public Security reported 203,049 road traffic accidents in 2019, with 62,763 fatalities and 226,751 injuries. The increased occurrence of traumatic injuries is increasing the demand for hemostatic agents in emergency and trauma care settings throughout Asia-Pacific.
• Furthermore, the Asia-Pacific region is experiencing an increase in cardiovascular disorders, which necessitate surgical procedures and the usage of hemostatic agents. According to the Asian Pacific Society of Cardiology, cardiovascular disease (CVD) causes 35% of all fatalities in the Asia Pacific region. According to the World Heart Federation, by 2030, 4.5 million people will die from cardiovascular disease in Southeast Asia alone, up from 3.6 million in 2014. The rising prevalence of cardiovascular disorders is driving up demand for hemostatic agents in heart surgery and associated treatments.

Europe:

• Europe region is estimated to exhibit substantial growth during the forecast period. Europe’s significant investment in healthcare infrastructure and research is fueling innovation and acceptance of improved hemostatic agents. The European Commission states that healthcare spending in the EU reached 9.9% of GDP in 2018, with an average annual increase rate of 3.0% between 2013 and 2018. Medtech Europe reports that the European medical technology market was valued at €120 billion in 2018. This strong healthcare spending and emphasis on medical technology advancement are boosting the hemostatic agents market in Europe, as hospitals and healthcare providers invest in cutting-edge technologies to improve patient outcomes.
• Furthermore, Europe has a high incidence of cardiovascular illnesses, which necessitate surgical treatments and the use of hemostatic agents. The European Heart Network claims that cardiovascular disease kills 3.9 million people in Europe each year, accounting for 45% of all deaths. According to the European Society of Cardiology, more than 11 million new instances of cardiovascular disease were diagnosed in Europe year 2015. The treatment of these disorders, particularly during surgical procedures, is driving up demand for hemostatic agents in the region.

Global Hemostatic Agents Market: Segmentation Analysis

The Hemostatic Agents Market is segmented based on Type, Product, Application, End-User, and Geography.

Hemostatic Agents Market, By Type

• Thrombin-based Hemostats
• Gelatin-based Hemostats
• Collagen-based Hemostats
• Oxidized Regenerated Cellulose-based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

Based on Type, the market is segmented into Thrombin-based, Gelatin-based, Collagen-based, Oxidized Regenerated Cellulose-based, Combination, Fibrin Sealants, and Others. The oxidized regenerated cellulose-based hemostats segment is estimated to dominate the hemostatic agents market during the forecast period. These hemostatic agents have emerged as market leaders, demonstrating their efficacy in a wide range of surgical procedures, including general surgery, cardiovascular surgery, orthopedics, and other specialties. This versatility has made them an appealing option for surgeons who face a variety of clinical settings, contributing to their dominant market position.

Hemostatic Agents Market, By Product

• Active
• Passive
• Combination
• Others

Based on Product, the market is segmented into Active, Passive, Combination, and Others. The passive segment is estimated to dominate the hemostatic agents market due to the wide range of product options and the growing popularity of technologically improved passive hemostatic solutions. These medicines are preferred for their efficacy in limiting bleeding during various surgical operations, resulting in increased acceptability among healthcare professionals. Also, the ongoing development of innovative passive hemostatic technologies by prominent manufacturers contributes to this segment’s market leadership.

Hemostatic Agents Market, By Application

• Trauma
• Cardiovascular Surgery
• General Surgery
• Plastic Surgery
• Orthopedic Surgery
• Neurosurgery
• Others

Based on Application, the market is divided into Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery, and Others. The general surgery segment is estimated to dominate the market over the forecast period. This dominance is driven by the growing number of surgical procedures performed worldwide, as general surgery comprises a wide range of operations that necessitate good bleeding control. The increased frequency of chronic diseases, as well as the demand for less invasive treatments, strengthen this segment, making it a vital area for hemostatic agent applications and contributing to its long-term market growth.

Hemostatic Agents Market, By End-User

• Hospitals
• Surgery Centers
• Nursing Homes
• Others

Based on End-User, the market is divided into Hospitals, Surgery Centers, Nursing Homes, and Others. The hospital segment is estimated to dominate the market over the forecast period due to the growing number of surgical procedures and the rising prevalence of chronic conditions that demand surgical interventions. Hospitals are prepared to manage difficult patients and provide comprehensive care, hence they are the principal environment for the administration of hemostatic drugs. As healthcare systems improve and expand, the need for good bleeding control in hospitals is projected to increase significantly.

Hemostatic Agents Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Hemostatic Agents Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate during the forecasted period. The region benefits from modern healthcare infrastructure, substantial healthcare spending, and a large number of surgical procedures per year. Furthermore, the existence of key market competitors and the ongoing launch of innovative hemostatic products support market growth. The growing need for technologically advanced surgical solutions reinforces North America’s leadership position in this market.

Key Players

The “Hemostatic Agents Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Baxter International, Inc., Becton, Dickinson and Company (BD), Pfizer, Inc., Ethicon, Inc., B. Braun SE, Teleflex Incorporated, CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, and GELITA AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Hemostatic Agents Market Recent Developments

• In November 2023, Johnson & Johnson’s MedTech division, Ethicon, launched Ethizia, a hemostatic sealing patch with European approval. This marks a substantial boost to the company’s medical services in Europe.
• In August 2023, Vizient Inc. issued HemoSonics an Innovative Technology Contract for their Quantra hemostasis system.

Report Scope

Research Methodology of Verified Market Research:

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team at Verified Market Research.

Reasons to Purchase this Report:

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

• In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.